Close Menu

NEW YORK – Expedeon has entered into a commercial agreement with Sona Nanotech with the intention of addressing limitations in the development of multiplex point-of-care lateral flow diagnostic tests.

Expedeon is a UK-based company specializing in development of tools for biological research, diagnostics, and drug discovery, while Sona is a Halifax, Canada-based maker of gold nanorod technologies for diagnostic applications and drug delivery.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.